GlassScriptPhysician profile
Pamela K Smith
NPI 1083621866
$11,153.13
in general payments reported to CMS, 2019-2025
38 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $676 · 2021: $1,324 · 2022: $1,584 · 2023: $2,217 · 2024: $1,741 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,375 · Education: $52.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,374.57 |
| Education | $52.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,007.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,514.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,204.68 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $842.36 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $693.32 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Amarin Pharma, INC. | $687.14 | 2019-2022 | |
| Pfizer INC. | $627.57 | 2019-2025 | |
| Glaxosmithkline, LLC. | $624.70 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $585.22 | 2019-2025 | Capvaxive, Belsomra, Steglatro |
| Dexcom, INC. | $429.44 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $285.43 | 2021-2024 | Nexletol |
| Abbvie INC. | $189.18 | 2023-2024 | Ubrelvy, Qulipta |
| Sanofi Pasteur INC. | $187.18 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.10 | 2019-2023 | Glyxambi, Trijardy Xr, Tradjenta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.